Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ADC Therapeutics (ADCT) EBIT Margin (2019 - 2026)

ADC Therapeutics has reported EBIT Margin over the past 8 years, most recently at 126.02% for Q1 2026.

  • Quarterly results put EBIT Margin at 126.02% for Q1 2026, up 44326.0% from a year ago — trailing twelve months through Mar 2026 was 216.07% (up 198.0% YoY), and the annual figure for FY2022 was 58.9%, up 62579.0%.
  • EBIT Margin reached 126.02% in Q1 2026 per ADCT's latest filing, up from 196.63% in the prior quarter.
  • Across five years, EBIT Margin topped out at 15666.65% in Q2 2023 and bottomed at 569.28% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 191.41% (2024), compared with a mean of 925.54%.
  • The largest annual shift saw EBIT Margin skyrocketed 2000000000bps in 2022 before it tumbled -1583718bps in 2024.
  • Over 5 years, EBIT Margin stood at 15.38% in 2022, then tumbled by -1521bps to 249.42% in 2023, then increased by 21bps to 197.4% in 2024, then increased by 0bps to 196.63% in 2025, then soared by 36bps to 126.02% in 2026.
  • Business Quant data shows EBIT Margin for ADCT at 126.02% in Q1 2026, 196.63% in Q3 2025, and 234.34% in Q2 2025.